Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
G1 makes the most of trilaciclib's unclear survival benefit
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
The venture money keeps flowing for biopharma
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.
